Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.

Cancer letters - 8 Jun 2008

Miyoshi Yasuo, Kurosumi Masafumi, Kurebayashi Junichi, Matsuura Nariaki, Takahashi Masato, Tokunaga Eriko, Egawa Chiyomi, Masuda Norikazu, Kim Seung Jin, Okishiro Masatsugu, Yanagisawa Tetsu, Ueda Satsuki, Taguchi Tetsuya, Tamaki Yasuhiro, Noguchi Shinzaburo

Abstract excerpt

Epirubicin exerts its anti-tumor effect through binding to topoisomerase IIalpha (TOP2A) and inducing DNA double-strand breaks. BRCA1 is involved in the repair of these breaks. We investigated the relationship between TOP2A or BRCA1 immunohistochemical expression and pathological response in 108...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to Combined Modality Therapy

Share to DNA Topoisomerases, Type II

Share to Epirubicin

Share to Neoplasm Staging

Share to Poly-ADP-Ribose Binding Proteins

Source

Identifiers

PMID: 18280644
DOI: 10.1016/j.canlet.2008.01.015

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18280644-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.PMID 18280644Read ↗

HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.Semantic proximity Read ↗

BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.Semantic proximity Read ↗

Triple negative breast cancer - current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessmentSemantic proximity Read ↗

The role of topoisomerase IIα and HER-2 in predicting sensitivity to anthracyclines in breast cancer patientsSemantic proximity Read ↗

Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.Semantic proximity Read ↗

BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.Semantic proximity Read ↗

BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis.Semantic proximity Read ↗

ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and PredictionSemantic proximity Read ↗

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).Semantic proximity Read ↗

[Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].Semantic proximity Read ↗

Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.Semantic proximity Read ↗

c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: a retrospective studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.